Duality Biologics (Suzhou) Co. Ltd. has entered into an exclusive option agreement with GSK plc for a preclinical antibody-drug conjugate (ADC) candidate, DB-1324.
Tubulis GmbH has sealed a potential $465 million option and licensing deal under which it will apply proprietary technologies to discover an antibody-drug conjugate (ADC) against a solid tumor target for Gilead Sciences Inc.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. won local approval of the first China-made trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), sacituzumab tirumotecan, as a third-line therapy for advanced breast cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. won local approval of the first China-made trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), sacituzumab tirumotecan, as a third-line therapy for advanced breast cancer.
Researchers from Pyxis Oncology Inc. presented preclinical data for PYX-201, an antibody drug conjugate (ADC) that targets extra domain B of fibronectin (EDB+FN).
Researchers from KU Leuven presented novel urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugates (ADC), ADCE-017 and ADCE-202, being developed for the treatment of soft tissue sarcoma.
Adcendo ApS has closed an oversubscribed $135 million series B financing round to support its development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.
Daiichi Sankyo Co. Ltd. and Astrazeneca plc have submitted a new BLA to the U.S. FDA for accelerated approval for datopotamab deruxtecan for treating locally advanced or metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer patients who have received prior systemic therapies.
Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.
Researchers from Exelixis Inc. described the preclinical characterization of XB-002, an antibody-drug conjugate consisting of a monoclonal antibody recognizing a tissue factor (TF) epitope that does not interfere with factor VII binding.